Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Archive
    • Podcast: NC Health Policy Forum
    • Upcoming Scientific Articles
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About Us
    • About the North Carolina Medical Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Help
    • RSS
  • Other Publications
    • North Carolina Medical Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
North Carolina Medical Journal
  • Other Publications
    • North Carolina Medical Journal
  • My alerts
  • Log in
North Carolina Medical Journal

Advanced Search

  • Home
  • Content
    • Current
    • Archive
    • Podcast: NC Health Policy Forum
    • Upcoming Scientific Articles
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About Us
    • About the North Carolina Medical Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Help
    • RSS
  • Follow ncmj on Twitter
  • Visit ncmj on Facebook
Research ArticleORIGINAL ARTICLE

Does Cancer Treatment-Related Financial Distress Worsen Over Time?

S.M. Qasim Hussaini, Fumiko Chino, Christel Rushing, Greg Samsa, Ivy Altomare, Jonathan Nicolla, Jeffrey Peppercorn and S. Yousuf Zafar
North Carolina Medical Journal January 2021, 82 (1) 14-20; DOI: https://doi.org/10.18043/ncm.82.1.14
S.M. Qasim Hussaini
hematology-oncology fellow, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland; former internal medicine resident, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shussa11@jh.edu
Fumiko Chino
radiation oncologist, Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York City, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christel Rushing
biostatistician, Duke Cancer Institute, Durham, North Carolina.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg Samsa
professor of biostatistics and bioinformatics, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivy Altomare
associate professor of medicine, Duke University School of Medicine; member, Duke Cancer Institute, Durham, North Carolina.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Nicolla
project director, Duke Cancer Institute, Durham, North Carolina.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Peppercorn
associate professor of medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Yousuf Zafar
associate professor of medicine, Duke University School of Medicine; member, Duke Cancer Institute, Durham, North Carolina.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

BACKGROUND Patients with cancer are at risk for both objective and subjective financial distress. Financial distress during treatment is adversely associated with physical and mental well-being. Little is known about whether patients’ subjective financial distress changes during the course of their treatment.

method This is a cross-sectional study of insured adults with solid tumors on anti-cancer therapy for ≥1 month, surveyed at a referral center and three rural oncology clinics. The goal was to investigate how financial distress varies depending on where patients are in the course of cancer therapy. Financial distress (FD) was assessed via a validated measure; out-of-pocket (OOP) costs were estimated and medical records were reviewed for disease/treatment data. Logistic regression was used to evaluate the potential association between treatment length and financial distress.

RESULTS Among 300 participants (86% response rate), median age was 60 years (range 27-91), 52.3% were male, 78.3% had stage IV cancer or metastatic recurrence, 36.7% were retired, and 56% had private insurance. Median income was $60,000/year and median OOP costs including insurance premiums were $592/month. Median FD score (7.4/10, SD 2.5) corresponded to low FD with 16.3% reporting high/overwhelming distress. Treatment duration was not associated with the odds of experiencing high/overwhelming FD in single-predictor (OR = 1.01, CI [.93, 1.09], P = .86) or multiple predictor regression models (OR = .98, CI [.86, 1.12], P = .79). Treatment duration was not correlated with FD as a continuous variable (P = .92).

LIMITATIONS This study is limited by its cross-sectional design and generalizability to patients with early-stage cancer and those being treated outside of a major referral center.

CONCLUSION Severity of cancer treatment-related financial distress did not correlate with time on treatment, indicating that patients are at risk for FD throughout the treatment continuum. Screening for and addressing financial distress should occur throughout the course of cancer therapy.

While advances in cancer treatment have improved outcomes for many patients with cancer, the associated rise in the cost of care due to new, expensive treatments has resulted in a growing financial burden borne by patients. These treatment-related expenses affect many aspects of patients’ lives, causing them to seek more work for additional income, spend less on food or clothing, and use their savings to pay for treatment [1]. Studies have also shown that relatively small increases in out-of-pocket health care costs can result in non-adherence to cancer treatment [2-4]. Treatment-related financial burden is adversely associated with physical and mental well-being [5-7]. A cancer diagnosis results in a 2.65 times higher risk of declaring personal bankruptcy [8]. The negative impact on patients’ well-being can cause such considerable distress that the term “financial toxicity” has been introduced to describe the negative side effects of high out-of-pocket costs in cancer care [9-11].

Studies have demonstrated that cancer treatment costs follow a U-shaped curve in which costs are highest in the year after diagnosis and in the last year of life, and lower in the intervening years [12]. These trends are consistent with higher-intensity treatments shortly after diagnosis, and the high costs of end-of-life care. The dimensions of these curves depend upon cancer site, stage at diagnosis, and type of treatment utilized. Much work remains to be done in describing whether personal, treatment-related financial burden varies over the course of cancer treatment [13]. Furthermore, the health system in its current form is often unable to identify patients before they fall into medical debt [14]. Understanding timing of financial burden would help health care providers identify patients who may benefit from targeted intervention to avoid financial toxicity.

In this study, we conducted a cross-sectional survey to explore the relationship between financial distress and the length of time the patient had been receiving anti-cancer treatment, and whether there are any patient or disease-related factors that increase the risk of financial distress.

Methods

Participants

Study design and methods have been previously described in detail [15-17]. Enrollment for the study occurred between November 2012 and June 2013 at a university-based cancer treatment center and three affiliated rural oncology clinics. Eligible patients had public or private insurance coverage, had a confirmed solid tumor cancer diagnosis, and were receiving anti-cancer hormonal therapy or chemotherapy for at least one month at the time of enrollment. Patients were excluded from the study if they were uninsured, were receiving radiation therapy, or did not speak English. Uninsured patients were excluded because we were focused primarily on the experiences of patients who were insured but were still at risk of financial distress. Underinsured patients were especially important to study because the hazard of being underinsured may remain despite the Affordable Care Act [18]. Underinsured was defined as having medical expenses greater than 10% of total income [19]. Patients receiving radiation were excluded due to the relatively short nature of a typical course of radiation therapy. The survey utilized in this study was pilot tested in a group of 20 patients at the Duke Cancer Institute and was approved by the Duke University Medical Center Institutional Review Board.

Study Design

A convenience sample of 349 patients who met eligibility criteria were approached while waiting in the clinic waiting room or receiving chemotherapy. Those who agreed to participate in the study were consented and given the survey in person by a trained interviewer. On rare occasions, the patient was enrolled and the survey administered on a second visit. Participants were given a gift of $10 for completion of the survey.

Main Outcome Measures

Demographic data such as cancer diagnosis, stage of disease, type of treatment (oral or IV chemotherapy or both), and duration of treatment were abstracted from the medical record. Patient-reported demographics were collected including annual household income, education, employment, medical costs, cost-related decision-making, and medication non-adherence [15-17]. Participants completed the InCharge Financial Distress/Financial Well-Being Scale, which is a validated, 8-item questionnaire that measures financial distress on a continuum [20]. Items were scored on a scale from 1 to 10 with 1 indicating overwhelming financial distress/lowest financial well-being, and 10 indicating no financial distress/highest financial well-being. From that a binary measure, “high/overwhelming financial distress” versus “low/average financial distress” was created. Time on treatment was abstracted from the medical record and defined as the length of time the patient had been receiving anti-cancer treatment at the time of study enrollment.

Statistical Analysis

The primary question of interest was whether time on treatment was related to subjective financial distress (FD). The correlation of months on treatment and continuous FD was tested using the Pearson correlation coefficient. To test for differences between those most affected by financial distress and those least affected, a binary version of the FD variable was created using < 4 as “high/overwhelming” distress and values of 4 or higher as “low/average” distress. Logistic regression was used to model binary FD. Patients were grouped by the binary FD variable and potential differences in demographic, clinical, and financial characteristics were evaluated using Wilcoxon rank sum tests for continuous variables and Fisher’s Exact or χ2 tests for categorical variables. To obtain appropriate odds ratios, two nested logistic models were fit: the base model with time on treatment as the sole predictor; and a second model (the anchor model) that adjusted for early versus late stage and receipt of oral chemotherapy. Both determined a priori to be important covariates. All statistical analyses were performed in SAS v9.4 (Cary, North Carolina).

Results

Patient demographics

As previously reported, 349 consecutive patients were approached in the clinic setting, and 300 were eligible and agreed to participate (86% response rate, Table 1) [15-17]. Median age was 60 years, 52.3% were male, and 72.3% had at least some postsecondary education. Full-time employment rate was 26.7% among participants, with 36.7% retirees. Overall, 40% of patients were underinsured and the median reported household income of study participants was $60,000. Of the 300 study participants, 290 (96.7%) had prescription drug coverage. All patients who participated in this study were receiving chemotherapy or hormonal therapy at the time of enrollment, with 72.3% receiving intravenous chemotherapy, 5.3% receiving oral anti-cancer agents, and 21.7% receiving both intravenous and oral therapies. Overall, 24.3% patients had metastatic recurrence and 54% were stage IV at diagnosis. As briefly reported in our previous work with this cohort (not included in this study), 22% did not fill a prescription because of cost; 52% expressed some desire to discuss treatment-related out-of-pocket costs; 19% had spoken to their doctor about costs; 57% reported lower out-of-pocket costs as a result of cost discussions; and there is 31% versus 10% relative cost of care for patients with high or overwhelming distress versus those with no, low, or average financial distress [15-17].

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1.

Demographic and Clinical Characteristics of Patient Cohort in Cross-Sectional Study Investigating Financial Distress

Time on Treatment and Financial Distress

The median duration of treatment was 4.6 months (range 1-156 months, Table 1). Although 4% of patients were on therapy for greater than five years, 73.7% were on chemotherapy or hormone treatment for a year or less with 55.3% on therapy for six months or less. Sixteen percent of patients (n = 49) classified their financial distress as high or overwhelming. The median financial distress score was 7.4, which corresponds to low degree of financial distress. The median monthly out-of-pocket expense was $591.50 (including insurance premiums).

Factors associated with financial distress

Factors associated with high financial distress are summarized in Table 2. Of respondents that had high-to-overwhelming financial distress, 57.1% were divorced, widowed, separated, or never married (versus 26.3% of respondents in the low-to-average FD group, P < .001). Similarly, employment was associated with financial distress. In participants with low-to-average financial distress, there was a 33.5% employment rate, with 42.2% retired and 20.3% unemployed and not seeking employment. In participants with high-to-overwhelming FD, there was a 28.6% employment rate with 8.2% retired and 57.1% unemployed and not seeking employment. Finally, underinsurance was associated with high financial distress (61.2% underinsured with high financial distress versus 35.9% underinsured with low financial distress, P < .001). These findings have been previously reported elsewhere by our group [17].

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 2.

Factors Associated with Financial Distress Defined as Low to Average versus High to Overwhelming

Multivariate Analysis

Logistic regression on duration of treatment, early versus late stage, and receipt of oral anti-cancer therapy demonstrated that early stage cancer was associated with a higher probability of high or overwhelming financial distress than late stage cancer (OR = 2.22 ; 95% CI, 1.11–4.43, P = .02) (Table 3). There was no association between time on treatment and binary financial distress on adjusted analysis.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 3.

Multivariate Analysis with Comparison between Time on Treatment, Early Stage vs Late Stage, and Mode of Therapy

Comparison of the continuous financial distress to duration of treatment yielded no evidence of a correlation (P = .92).

Discussion

A large portion of cancer patients undergoing anti-cancer therapy experience financial distress as a direct result of their treatment [1, 21, 22]. In this cross-sectional study, we found no correlation between severity of their financial distress and duration of treatment. However, having early-stage cancer was associated with a higher level of financial distress.

Our data suggest that, unlike systemic costs, subjective financial burden does not necessarily vary over the course of treatment. The potential for financial distress regardless of time on treatment is supported by studies that suggest long-term cancer survivors are also at risk for experiencing financial burden. Kent and colleagues, using data from the National Health Interview Survey, found that 32% of cancer survivors reported cancer-related financial problems [21]. Guy and colleagues found that the financial burden related to cancer treatment, including direct and indirect costs, remained high years after diagnosis [23]. An explanation for the durability of financial burden might relate to employment in survivorship as well: De Boer and colleagues found that cancer survivors were more likely to be unemployed than healthy control participants [24-26]. Indeed, our current study shows unemployment is significantly associated with financial distress.

While duration of treatment was not associated with severity of financial distress, stage might serve as a more predictable marker of financial burden for certain types of cancers [27]. This may be due to higher costs incurred in the initial period following diagnosis [12, 27]. This is further underscored by the increasing frequency of plans with higher deductibles (promising lower premiums) as well as new, expensive oral regimens. Oral medications have become an increasingly common mode of anti-cancer drug delivery compared to traditional intravenous chemotherapy. This has presented unique challenges for the patient including medication adherence and cost partly due to limited prescription drug coverage [28-30]. Financial assistance continues to remain small in such cases [30]. Similarly, our study suggests that lack of prescription drug coverage is associated with financial distress. It is an area that will require greater scrutiny and policy-level changes [31]. As previously reported [6, 7, 17] and demonstrated in this study, characteristics such as age and marital status might be useful for targeting early interventions in patients who are at risk for treatment-related financial distress. This is not unique to patients in the United States. Similar results were reported in a study evaluating financial distress in patients with advanced cancer in France [32].

An alternative to patients making significant lifestyle changes to accommodate unexpected out-of-pocket costs, clear predictors of financial distress could help providers anticipate distress and direct patients to the appropriate resources. Our results indicate that patients are at risk for significant financial distress throughout their care and that health care providers should intermittently inquire about financial well-being during a patient visit as they would about medication side effects or new symptoms. Recently developed measures have demonstrated reliability and validity in measuring financial toxicity in patients with advanced cancer [33, 34]. These measures have shown correlation to health-related quality of life and may be utilized in the clinical setting to help guide efforts with patients.

Limitations

This study has several limitations. First, we reported a cross-sectional analysis of the sample population at one point in their treatment, which may not account for changes in financial distress over time. Second, financial distress was self-reported, leading to the possibility of recall bias and socially desirable response bias. Third, there were fewer than 50 total patients who reported high to overwhelming distress, limiting the power to detect differences. Fourth, we surveyed a consecutive but nonrandom sample of cancer patients, most of whom were treated at a major referral center. However, the study had a high response rate and non-responders only differed to responders in age, suggesting that at least within this center, this was a representative population. Fifth, the median monthly out-of-pocket cost estimates provided by study participants approximated those from larger, population-based studies [35, 36]. This study was conducted at a large referral center and three rural oncology clinics, and median annual household income in the study was higher than median household income in the United States. However, that suggests that financial distress might be even higher in a more nationally representative population. Sixth, since our patient cohort included majority advanced cancer patients, it may not adequately represent financial distress in patients with early stage cancer. Furthermore, uninsured patients were excluded in this study since we were focused primarily on the experiences of patients who were insured but were still at risk of financial distress. Patients receiving radiation were excluded due to the relatively short nature of a typical course of radiation therapy. Finally, since not all potentially eligible patients were approached due to study staff availability, selection bias might have been introduced.

Conclusion

In this study, duration of cancer treatment was not found to be associated with treatment-related financial distress, suggesting patients may be at risk for developing financial distress throughout their treatment continuum. Receiving curative-intent treatment was found to be significantly associated with high financial distress, independent of treatment duration. Underinsurance, unemployment, and single/divorced/widowed marital status were other factors found associated with high financial distress. Further research is needed to develop and apply innovative interventions to identify patients at risk for treatment-related financial burden.

Acknowledgments

S.M. Qasim Hussaini, Fumiko Chino, and Christel Rushing helped with hypothesis generation, data interpretation, and writing the manuscript. Christel Rushing and Greg Samsa helped in data collection and interpretation. Ivy Altomare, Jonathan Nicolla, Jeffrey Peppercorn, and S. Yousuf Zafar provided overall guidance and support in successful completion of this project. This work was supported by the Duke Cancer Institute Cancer Control Pilot Studies Program (S. Yousuf Zafar) and Duke Clinical Research Institute Comparative Effectiveness KM1 Award No. 1KM1CA156687-01 (S. Yousuf Zafar)

Potential conflicts of interest. S.Y.Z. reports other from AIM Specialty Health, non-financial support and other from Vivor, LLC, nonfinancial support and other from SamFund, non-financial support from Family Reach Foundation, other from Copernicus-WCG IRB, personal fees from RTI, personal fees from McKesson, other from Shattuck Labs, grants from Astrazeneca, grants from NIH, outside the submitted work. J.N. is listed as contributor on Duke-filed Inventor Disclosure Form for Pathlight, a research-based application built to help patients have financial discussions with their oncologist. J.P. reports other from GlaxoSmithKline, grants from Pfizer, outside the submitted work. All other authors list no conflicts of interest. We have full control of primary data, and we agree to have the journal review the data if needed.

  • ©2021 by the North Carolina Institute of Medicine and The Duke Endowment. All rights reserved.

References

  1. 1.↵
    1. Zafar SY,
    2. Peppercorn JM,
    3. Schrag D, et al.
    The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18(4):381-390. doi: 10.1634/theoncologist.2012-0279
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Dusetzina SB,
    2. Winn AN,
    3. Abel GA, et al.
    Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clini Oncol. 2014;32(4):306-311. doi: 10.1200/JCO.2013.52.9123
    OpenUrlCrossRef
  3. 3.
    1. Neugut AI,
    2. Subar M,
    3. Wilde ET, et al.
    Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534-2542. doi: 10.1200/JCO.2010.33.3179
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Weaver KE,
    2. Rowland JH,
    3. Bellizzi KM, et al.
    Forgoing medical care because of cost: Assessing disparities in healthcare access among cancer survivors living in the united states. Cancer. 2010;116(14):3493-3504. doi: 10.1002/cncr.25209
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Kale HP,
    2. Carroll NV.
    Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among us cancer survivors. Cancer. 2016;122(8):283-289. doi: 10.1002/cncr.29808
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Meeker CR,
    2. Wong YN,
    3. Egleston BL, et al.
    Distress and financial distress in adults with cancer: An age-based analysis. J Natl Compr Canc Netw. 2017;15(10):1224-1233. doi: 10.6004/jnccn.2017.0161
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Carrera PM,
    2. Kantarjian HM,
    3. Blinder VS.
    The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153-165. doi: 10.3322/caac.21443
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Ramsey S,
    2. Blough D,
    3. Kirchhoff A, et al.
    Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32(6):1143-1152. doi: 10.1377/hlthaff.2012.1263
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Ubel PA,
    2. Abernethy AP,
    3. Zafar SY.
    Full disclosure — out-of-pocket costs as side effects. New Engl J Med. 2013;369(16):1484-1486. doi: 10.1056/NEJMp1306826
    OpenUrlCrossRefPubMed
  10. 10.
    1. Zafar SY and Abernethy AP.
    Financial toxicity, part i: A new name for a growing problem. Oncology (Williston Park). 2013;27(2):80-81, 149.
    OpenUrlPubMed
  11. 11.↵
    1. Zafar SY.
    Financial toxicity of cancer care: It’s time to intervene. J Natl Cancer Inst. 2016;108(5):djv370. doi: 10.1093/jnci/djv370
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Yabroff KR,
    2. Lund J,
    3. Kepka D, et al.
    Economic burden of cancer in the united states: Estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2006-2014. doi: 10.1158/1055-9965.EPI-11-0650
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Chino F,
    2. Peppercorn JM,
    3. Rushing C, et al.
    Going for broke: A longitudinal study of patient-reported financial sacrifice in cancer care. J Oncol Pract. 2018;14(9):e533-e546. doi: 10.1200/JOP.18.00112
    OpenUrlCrossRef
  14. 14.↵
    1. Smith SK,
    2. Nicolla J,
    3. Zafar SY.
    Bridging the gap between financial distress and available resources for patients with cancer: A qualitative study. J Oncol Pract. 2014;10(5):e368-e372. doi: 10.1200/JOP.2013.001342
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Bestvina CM,
    2. Zullig LL,
    3. Rushing C, et al.
    Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014;10(3):162-167. doi: 10.1200/JOP.2014.001406
    OpenUrlAbstract/FREE Full Text
  16. 16.
    1. Zafar SY,
    2. Chino F,
    3. Ubel PA, et al.
    The utility of cost discussions between patients with cancer and oncologists. Am J Manag Care. 2015;21(9):607-615.
    OpenUrlPubMed
  17. 17.↵
    1. Chino F,
    2. Peppercorn JM,
    3. Rushing C, et al.
    Out-of-pocket costs, financial distress, and underinsurance in cancer care. JAMA Oncol. 2017;3(11):1582-1584. doi: 10.1001/jamaoncol.2017.2148
    OpenUrlCrossRef
  18. 18.↵
    1. Andrews M.
    Despite Health Law’s Protections, Many Consumers May Be ‘Uninsured.’ KHN.org. http://www.kaiserhealthnews.org/Stories/2013/December/31/Michelle-Andews-health-law-protections-consumers. Published Decemer 31, 2013. Accessed April 1, 2014.
  19. 19.↵
    1. Schoen C,
    2. Doty MM,
    3. Robertson RH, et al.
    Affordable care act reforms could reduce the number of underinsured us adults by 70 percent. Health Aff (Millwood). 2011;30(9):1762-1771. doi: 10.1377/hlthaff.2011.0335
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Prawitz AD,
    2. Garman ET,
    3. Sorhaindo B, et al.
    Incharge financial distress/financial well-being scale: Development, administration, and score interpretation. Financ Counsel Plan. 2006;17(1):34-50.
    OpenUrl
  21. 21.↵
    1. Kent EE,
    2. Forsythe LP,
    3. Yabroff KR, et al.
    Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119(20):3710-3717. doi: 10.1002/cncr.28262
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Fenn KM,
    2. Evans SB,
    3. McCorkle R, et al.
    Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract. 2014;10(5):332-338. doi: 10.1200/JOP.2013.001322
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Guy GP,
    2. Ekwueme DU,
    3. Yabroff KR, et al.
    Economic burden of cancer survivorship among adults in the united states. J Clin Oncol. 2013;31(30):3749-3757. doi: 10.1200/JCO.2013.49.1241
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. de Boer AM,
    2. Taskila T,
    3. Ojajärvi A, et al.
    Cancer survivors and unemployment: A meta-analysis and meta-regression. JAMA. 2009;301(7):753-762. doi: 10.1001/jama.2009.187
    OpenUrlCrossRefPubMed
  25. 25.
    1. Lauzier S,
    2. Maunsell E,
    3. Drolet M, et al.
    Wage losses in the year after breast cancer: Extent and determinants among canadian women. J Natl Cancer Inst. 2008;100(5):321-332. doi: 10.1093/jnci/djn028
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Longo CJ,
    2. Fitch M,
    3. Deber RB, et al.
    Financial and family burden associated with cancer treatment in ontario, canada. Support Care Cancer. 2006;14(11):1077-1085. doi: 10.1007/s00520-006-0088-8
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Kaye DR MH,
    2. Herrel LA,
    3. Dupree JM,
    4. Ellimoottil C,
    5. MIller DC.
    Costs of cancer care across the disease continuum. Oncologist. 2018;23(7):798-805. doi: 10.1634/theoncologist.2017-0481
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Greer JA,
    2. Amoyal N,
    3. Nisotel L, et al.
    A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21(3):354-376. doi: 10.1634/theoncologist.2015-0405
    OpenUrlAbstract/FREE Full Text
  29. 29.
    1. Shih YC,
    2. Smieliauskas F,
    3. Geynisman DM, et al.
    Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol. 2015;33(19):2190-2196. doi: 10.1200/JCO.2014.58.2320
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Zullig LL,
    2. Wolf S,
    3. Vlastelica L, et al.
    The role of patient financial assistance programs in reducing costs for cancer patients. J Manag Care Spec Pharm. 2017;23(4):407-411. doi: 10.18553/jmcp.2017.23.4.407
    OpenUrlCrossRef
  31. 31.↵
    1. Peppercorn J.
    Financial toxicity and societal costs of cancer care: Distinct problems require distinct solutions. Oncologist. 2017;22(2):123-125. doi: 10.1634/theoncologist.2016-0301
    OpenUrlFREE Full Text
  32. 32.↵
    1. Barbaret C,
    2. Brosse C,
    3. Rhondali W, et al.
    Financial distress in patients with advanced cancer. PLoS One. 2017;12(5):e0176470. doi: 10.1371/journal.pone.0176470
    OpenUrlCrossRef
  33. 33.↵
    1. de Souza JA,
    2. Yap BJ,
    3. Hlubocky FJ, et al.
    The development of a financial toxicity patient-reported outcome in cancer: The cost measure. Cancer. 2014;120(20):3245-3253. doi: 10.1002/cncr.28814
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. de Souza JA,
    2. Yap BJ,
    3. Wroblewski K, et al.
    Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the comprehensive score for financial toxicity (COST). Cancer. 2017;123(3):476-484. doi: 10.1002/cncr.30369
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Bernard DSM,
    2. Farr SL,
    3. Fang Z.
    National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011;29(20):2821-2826. doi: 10.1200/JCO.2010.33.0522
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Davidoff AJ,
    2. Erten M,
    3. Shaffer T, et al.
    Out-of-pocket health care expenditure burden for medicare beneficiaries with cancer. Cancer. 2012;119(6):1257-1265. doi: 10.1002/cncr.27848
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

North Carolina Medical Journal: 82 (1)
North Carolina Medical Journal
Vol. 82, Issue 1
January/February 2021
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on North Carolina Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Does Cancer Treatment-Related Financial Distress Worsen Over Time?
(Your Name) has sent you a message from North Carolina Medical Journal
(Your Name) thought you would like to see the North Carolina Medical Journal web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Does Cancer Treatment-Related Financial Distress Worsen Over Time?
S.M. Qasim Hussaini, Fumiko Chino, Christel Rushing, Greg Samsa, Ivy Altomare, Jonathan Nicolla, Jeffrey Peppercorn, S. Yousuf Zafar
North Carolina Medical Journal Jan 2021, 82 (1) 14-20; DOI: 10.18043/ncm.82.1.14

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Does Cancer Treatment-Related Financial Distress Worsen Over Time?
S.M. Qasim Hussaini, Fumiko Chino, Christel Rushing, Greg Samsa, Ivy Altomare, Jonathan Nicolla, Jeffrey Peppercorn, S. Yousuf Zafar
North Carolina Medical Journal Jan 2021, 82 (1) 14-20; DOI: 10.18043/ncm.82.1.14
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Limitations
    • Conclusion
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Using a Community Engagement Approach to Enhance Contraception Awareness in Rural Western North Carolina
  • Characteristics of an Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury—North Carolina, 2019
  • A Needs Assessment of Persons With Sickle Cell Disease in a Major Medical Center in North Carolina
Show more ORIGINAL ARTICLE

Similar Articles

About & Contact

  • About the NCMJ
  • Editorial Board
  • Feedback

Info for

  • Advertisers
  • Authors
  • Reviewers
  • Subscribers

Articles & Alerts

  • Archive
  • Current Issue
  • Get Alerts
  • Upcoming Articles

Additional Content

  • Current NCIOM Task Forces
  • NC Health Data & Resources
  • NCIOM Blog
North Carolina Medical Journal

ISSN: 0029-2559

© 2022 North Carolina Medical Journal

Powered by HighWire